title: Catheter-based treatment for patients with acute ischemic stroke ineligible for intravenous thrombolysis.
abstract: OBJECTIVE
  We present our single-center experience using catheter-based therapy for acute ischemic stroke patients who were not candidates for intravenous thrombolytic therapy.
  
  
  METHODS
  Neurologic outcomes were assessed in patients with acute ischemic stroke, ineligible for intravenous thrombolysis, treated with an emergent catheter-based therapy.
  
  
  RESULTS
  Nonparametric analysis of neurological outcomes demonstrated a benefit in National Institutes of Health Stroke Scale (NIHSS) at long-term follow-up (P=0.036). Independence in daily activities and improvement in NIHSS of > or =4 points were achieved in 38% and 56% of patients, respectively. Four patients (25%) died, including 2 patients (12.5%) who died from intracranial hemorrhage.
  
  
  CONCLUSIONS
  Catheter-based treatment offers a promising treatment strategy in patients with acute ischemic stroke ineligible for intravenous thrombolysis.
authors.affiliation: Department of Cardiology, Ochsner Clinic Foundation, 1514 Jefferson Highway, New Orleans, La 70121, USA. sramee@ochsner.org
authors.forename: Stephen R
authors.initials: SR
authors.lastname: Ramee
authors.forename: Rajesh
authors.initials: R
authors.lastname: Subramanian
authors.forename: Robert A
authors.initials: RA
authors.lastname: Felberg
authors.forename: Kevin L
authors.initials: KL
authors.lastname: McKinley
authors.forename: J Stephen
authors.initials: JS
authors.lastname: Jenkins
authors.forename: Tyrone J
authors.initials: TJ
authors.lastname: Collins
authors.forename: Robert C
authors.initials: RC
authors.lastname: Dawson
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: White
mesh_terms: D000368:Aged; D000800:Angioplasty, Balloon / Q000379:methods*; D002545:Brain Ischemia / Q000175:diagnosis / Q000188:drug therapy* / Q000628:therapy*; D005260:Female; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D020244:Infarction, Middle Cerebral Artery / Q000517:prevention & control; D007261:Infusions, Intra-Arterial; D020300:Intracranial Hemorrhages / Q000517:prevention & control; D008297:Male; D012720:Severity of Illness Index; D018709:Statistics, Nonparametric; D015607:Stents; D020521:Stroke / Q000175:diagnosis / Q000188:drug therapy* / Q000628:therapy*; D015912:Thrombolytic Therapy / Q000379:methods*; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D016896:Treatment Outcome; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use
chemical_list: D006493:Heparin; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator